CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation…
Cell and Gene Therapies (CGTs) present unique development challenges, from novel manufacturing processes and delivery methods to complex nonclinical programs and evolving regulatory expectations. For sponsors developing these therapies, engaging with the FDA early and often can help clarify development…
Slide Presentation: TCT 192: Outcomes of Non-STEMI hospitalizations in Patients with comorbid Cancer
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers. The Institute for Value-Based Medicine®, hosted by The American Journal of Managed Care® (AJMC®), held its October 1, 2026, meeting in Birmingham,…
The extensive data to be presented at ESMO 2026 reflect Akeso's ongoing commitment to advancing next-generation immuno-oncology therapies for major global diseases and our continued efforts to build a differentiated global oncology portfolio. Full results will be released during the Congress.
VMPL New Delhi [India], October 27: Actorius Innovations and Research today presented its integrated liquid biopsy portfolio at the CAMO 2026 – Cancer in Motion International Scientific Symposium held at ACTREC, Tata Memorial Centre, Navi Mumbai. At the event, the company launched its…
Data support potential for highly differentiated clinical impact for patients suffering from metastatic prostate cancer Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T, an investigational multi-target immunotherapy platform for solid tumors, today announced updated overall survival results from…
2026 European Society for Medical Oncology (ESMO) Annual Congress To address this question, Dr. Mertens organized her presentation around five considerations: Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the 2026 EAU guidelines…
Target Population Selection: Biomarker profile – applied prior to treatment of locally advanced disease with no lymph node involvement (N0) and low/zero tumor PD-L1 expression (TPS Nearly 3x Higher Pre-Surgical Response: New analysis demonstrated a statistically significant increase in pre-surgical response/disease…
Xencor shares jumped 31% after its kidney cancer drug XmAb819 had a 45.5% confirmed response rate in heavily pre-treated patients at the dose it chose. The data gives Xencor a credible case for accelerated approval in patients who have run out of standard…
What is presented at medical meetings: ASCO, ESMO, EASD, ASH, AACR, the World Conference on Lung Cancer and other congresses.
An article joins this feed when it matches these terms. Each one is also a search of its own.